Physician profile
Manuel A Lopez
NPI 1770505984
$55,220.81
in general payments reported to CMS, 2019-2025
8 companies · $13K in 2025
The $13K reported for 2025 was more than what 97% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $578 · 2021: $8,539 · 2022: $9,967 · 2023: $9,299 · 2024: $13K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18,566.17 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,911.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $19,863.55 | 2019-2023 | |
| Abbvie INC. | $18,214.88 | 2023-2025 | |
| Lumenis Be INC | $13,927.99 | 2024-2025 | M22 |
| Galderma Laboratories, L.P. | $2,380.46 | 2019-2025 | Dysport |
| Merz North America, INC. | $494.70 | 2019 | |
| Revance Therapeutics, INC. | $228.17 | 2024-2025 | Daxxify |
| Ardelyx, INC. | $62.81 | 2025 | Ibsrela |
| Urgo Medical North America, LLC | $48.25 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.